Skip to main content

CORRECTION article

Front. Pharmacol., 11 November 2021
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.796551

Corrigendum: Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis

This article is a correction to:

  1. Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis

    1. Read original article
Hongwei Shi,&#x;Hongwei Shi1,2†Heng Tang&#x;Heng Tang3†Wen AiWen Ai4Qingfu ZengQingfu Zeng5Hong YangHong Yang6Fengqing ZhuFengqing Zhu3Yunjie WeiYunjie Wei7Rui FengRui Feng3Li WenLi Wen3Peng Pu Peng Pu3*Quan He Quan He3*
  • 1Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • 2Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China
  • 3Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 4Shenzhen Nanshan District People’s Hospital, Shenzhen, China
  • 5Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 6Department of Endocrine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 7Department of Cardiology, Hubei Shiyan Taihe Hospital, Shiyan, China

A Corrigendum on
Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis

by Shi, H., Tang, H., Ai, W., Zeng, Q., Yang, H., Zhu, F., Wei, Y., Feng, R., Wen, L., Pu, P., and He, Q. (2021) Front. Pharmacol. 12:733805. doi: 10.3389/fphar.2021.733805

In the original article, there was an error in the Funding section. We neglected to include “National Key R&D Program of China (Grant numbers: 2018YFC1311400, 2018YFC1311404)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: schisandrin B, cardiotoxicity, anti-apoptotic pirarubicin, anti-apoptotic, THP

Citation: Shi H, Tang H, Ai W, Zeng Q, Yang H, Zhu F, Wei Y, Feng R, Wen L, Pu P and He Q (2021) Corrigendum: Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis. Front. Pharmacol. 12:796551. doi: 10.3389/fphar.2021.796551

Received: 17 October 2021; Accepted: 25 October 2021;
Published: 11 November 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Shi, Tang, Ai, Zeng, Yang, Zhu, Wei, Feng, Wen, Pu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Peng Pu, pp841103@sina.com; Quan He, 851557800th@sina.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.